Latest
Maladaptive Neuroplasticity in Cortico-limbic Structures: Insights from Surgical Pain Relief in Chronic Neuropathic Facial Pain
Targeting the Endocannabinoid System for Management of Chemotherapy, HIV and Antiretroviral-Induced Neuropathic Pain
Chemotherapeutic drugs (used for treating cancer), HIV infection and antiretroviral therapy (ART) can independently cause difficult-to-manage painful neuropathy. Paclitaxel, a chemotherapeutic drug, for example is associated with high incidence of peripheral neuropathy, around 71% of the patients of which 27% of these develop neuropathic pain. Use of cannabis or phytocannabinoids has been reported to improve pain measures in patients with neuropathic pain, including painful HIV-associated sensory neuropathy and cancer pain. Phytocannabinoids and endocannabinoids, such as anandamide and 2-arachidonoylglycerol (2-AG), produce their effects via cannabinoid (CB) receptors, which are present both in the periphery and central nervous system. Endocannabinoids are synthesized in an “on demand” fashion and are degraded by various enzymes such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL). Various studies, including those from our group, suggest that there are changes in gene and protein expression of endocannabinoid molecules during chemotherapy-induced neuropathic pain (CINP), HIV and antiretroviral-induced neuropathic pain. Analysis of endocannabinoid molecule expression in the brain, spinal cord and paw skin using LC-MS/MS show that there is a specific deficiency of the endocannabinoids 2-AG and/or anandamide in the periphery during CINP. Various drugs including endocannabinoids, cannabidiol, inhibitors of FAAH and MGL, CB receptor agonists, desipramine and coadministered indomethacin plus minocycline have been found to either prevent the development and/or attenuate established CINP, HIV and antiretroviral-induced neuropathic pain in a CB receptor-dependent manner. The results available suggest that targeting the endocannabinoid system for prevention and treatment of CINP, HIV-associated neuropathic pain and antiretroviral-induced neuropathic pain is a plausible therapeutic option.
Antiallodynia and antihyperalgesia effects of Cerium oxide nanoparticles in treatment of chronic neuropathic pain in rats
Altered parabrachial nucleus nociceptive processing may underlie central neuropathic pain in Parkinson’s disease
Centrally expressed Cav3.2 T-type calcium channel is critical for the initiation and maintenance of neuropathic pain
Daily record with portable EEG in SCI patients with neuropathic pain
Dual PI3Kδ/γ inhibitor Duvelisib prevents development of chemotherapy induced neuropathic pain
Functional alterations of intrinsic networks at various stages of neuropathic pain and comorbidity development
AAV gene therapy delivering recombinant dimeric peptides targeting PICK1 fully relieve chronic neuropathic pain
Glial activation contributes to increased sensitivity of spinal TRPV1 receptors in paclitaxel induced neuropathic pain
Involvement of parvalbumin-positive GABAergic neurons in basal forebrain modulation in a mouse model of neuropathic pain
Microglial P2X4 in neuropathic pain and associated comorbidities: A gender independent story?
Repetitive prefrontal transcranial direct current stimulation alleviates neuropathic pain via neural remodelling
Role of voltage-dependent potassium currents on trigeminal neuropathic pain
Spinal Cav3.2 T-type channels impact on neuropathic pain: toward translating rodent findings to human pathophysiology
Study of the antinociceptive effect of morphine evaluated by a neuropathic pain model in male and female mice
Trigeminal neuropathic pain alters ultrasonic vocalizations in rats restored by analgesic drugs
Add content
Have a seminar, talk, or paper on neuropathic pain? Post it so others working in this area can find it.
Post content